In vitro and animal models of drug-induced blood dyscrasias

Environmental Toxicology and Pharmacology

Volumn 21, Issue 2 SPEC. ISS., 2006, Pages 135-140

  Ip, Julia ^a   Uetrecht, Jack P ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Agranulocytosis; Aplastic anemia; Idiosyncratic drug reactions; Reactive metabolites; Thrombocytopenia

Indexed keywords

AMINOGLUTETHIMIDE; AMINOPHENAZONE; AMODIAQUINE; ANTINEOPLASTIC AGENT; CLOZAPINE; DIPYRONE; FELBAMATE; MYELOPEROXIDASE; OLANZAPINE; PIPERANOMETOZINE; QUINIDINE; REMOXIPRIDE;

AGRANULOCYTOSIS; ANIMAL MODEL; APLASTIC ANEMIA; BLOOD DYSCRASIA; BONE MARROW TOXICITY; DISEASE SEVERITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; HUMAN; IDIOPATHIC DISEASE; IN VITRO STUDY; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANIMALIA;

EID: 31544478506     PISSN: 13826689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etap.2005.07.003     Document Type: Article

References (45)

1. S. Aizawa, M. Nakano, M. Yaguchi, Y. Kuriyama, O. Iwase, K. Toyama, K. Tanaka, H. Hoshi, K. Sugimoto, A. Kaido, T. Imai, R. Nabeshima, and H. Handa Possible involvement of bone marrow stromal cells in agranulocytosis caused by vesnarinone treatment Acta Haematol. 98 1997 140 146
2. H. Ali, and P.J. Nicholls Haematological effects of aminoglutethimide in the mouse J. Pharm. Pharmcol. 38 1986 92P
3. R.H. Aster Drug-induced immune thrombocytopenia: an overview of pathogenesis Semin. Hematol. 36 1999 2 6
4. K. Atkin, F. Kendall, D. Gould, H. Freeman, J. Liberman, and D. O'Sullivan Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland Br. J. Psychiatry 169 1996 483 488
5. J.P. Aymard, C. Wioland, R. Ferry, P. Netter, and F. Streiff The in vitro effect of amodiaquine on bone marrow granulocyte-macrophage progenitor cells from normal subjects Fundam. Clin. Pharmacol. 6 1992 1 4
6. G. Caldwell, A. Bradbury, and A.D. Toft Aminoglutethimide-induced agranulocytosis in breast cancer Br. Med. J. 291 1985 970
7. J.B. Clarke, J.L. Maggs, N.R. Kitteringham, and B.K. Park Immunogenicity of amodiaquine in the rat Int. Arch. Allergy Appl. Immunol. 91 1990 335 342
8. J.B. Clarke, K. Neftel, N.R. Kitteringham, and B.K. Park Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine Int. Arch. Allergy Appl. Immunol. 95 1991 369 375
9. M.D. Coleman, L.F. Khalaf, and P.J. Nicholls Environ. Toxicol. Pharmacol. 15 2003 27 32
10. G.L. Deliliers, F. Servida, G. Lamorte, N. Quirici, and D. Soligo In vitro effect of clozapine on hemopoietic progenitor cells Haematologica 83 1998 882 889
11. C. Dieckhaus, T. Miller, R.D. Sofia, and T. Macdonald A mechanistic approach to understanding the species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions Chem. Res. Toxicol. 28 2000 814 822
12. T.E. Eling, R.P. Mason, and K. Sivarajah The formation of aminopyrine cation radical by peroxidase activity of prostaglandin H synthase and subsequent reactions of the radical J. Biol. Chem. 260 1985 1601 1607
13. J.C. Erve, M.A. Svensson, H. von Euler-Chelpin, and E. Klasson-Wehler Characterization of glutathione conjugates of the remoxipride hydroquinone metabolite NCQ-344 formed in vitro and detection following oxidation by human neutrophils Chem. Res. Toxicol. 17 2004 564 571
14. D.C. Evans, A.P. Watt, D.A. Nicoll-Griffith, and T.A. Baillie Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17 2004 3 16
15. B. Fulton, and K.L. Goa Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses Drugs 53 1997 281 298
16. I. Gardner, J.S. Leeder, T. Chin, N. Zahid, and J.P. Uetrecht A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo Mol. Pharmacol. 53 1998 999 1008
17. I. Gardner, N. Zahid, D. MacCrimmon, and J.P. Uetrecht A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes Mol. Pharmacol. 53 1998 991 998
18. L. Gribaldo, J. Bueren, A. Deldar, P. Hokland, C. Meredith, D. Moneta, P. Mosesso, R. Parchment, D. Parent-Massin, A. Pessina, J. San Roman, and G. Schoeters The use of in vitro systems for evaluating haematotoxicity Altern. Lab. Anim. 24 1996 211 231
19. I. Guest, B. Sokoluk, J. MacCrimmon, and J. Uetrecht Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis Toxicology 131 1998 53 65
20. K. Hedenmalm, and O. Spigset Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole) Eur. J. Clin. Pharmacol. 58 2002 265 274
21. A.M. Hoffman, E.M. Butt, and N.G. Hickey Neutropenia following amidopyrine J. Am. Med. Assoc. 102 1934 1213 1214
22. I.M. Kapetanovic, C.D. Torchin, C.D. Thompson, T.A. Miller, P.J. McNeilly, T.L. Macdonald, H.J. Kupferberg, J.L. Perhach, R.D. Sofia, and J.M. Strong Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro Drug Metab. Dispos. 26 1998 1089 1095
23. Z.C. Liu, and J.P. Uetrecht Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells J. Pharmacol. Exp. Ther. 275 1995 1476 1483
24. J.L. Maggs, M.D. Tingle, N.R. Kitteringham, and B.K. Park Drug-protein conjugates-XIV: mechanisms of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatoxin in man Biochem. Pharmacol. 37 1988 303 311
25. J.L. Maggs, D. Williams, M. Pirmohamed, and B.K. Park The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man J. Pharmacol. Exp. Ther. 275 1995 1463 1475
26. S.M. McGuinness, R. Johansson, J. Lundstrom, and D. Ross Induction of apoptosis by remoxipride metabolites in HL60 and CD34+/CD19-human bone marrow progenitor cells: potential relevance to remoxipride-induced aplastic anemia Chem. Biol. Interact. 121 1999 253 265
27. A.A. Messeih, A. Lipton, R.J. Santen, H.A. Harvey, A.E. Boucher, R. Murray, J. Ragaz, A.U. Buzdar, G.A. Nagel, and I.C. Henderson Aminoglutethimide-induced hematologic toxicity: worldwide experience Cancer Treat. Rep. 69 1985 1003 1004
28. S. Moeschlin, and K. Wagner Agranulocytosis due to the occurrence of leukocyte-agglutinins Acta Haematol. 8 1952 29 41
29. G.D. Negro, M. Bonato, and L. Gribaldo In vitro bone marrow granulocyte-macrophage progenitor cultures in the assessment of hematotoxic potential of the new drugs Cell Biol. Toxicol. 17 2001 95 105
30. D.M. Parent-Massin, L. Sensebe, M.C. Leglise, G. Guern, C. Berthou, C. Riche, and J.F. Abgrall Relevance of in vitro studies of drug-induced agranulocytosis. Report of 14 cases Drug Saf. 9 1993 463 469
31. B.K. Park, M. Pirmohamed, and N.R. Kitteringham Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective Chem. Res. Toxicol. 11 1998 969 988
32. A. Pessina, B. Albella, M. Bayo, J. Bueren, P. Brantom, S. Casati, C. Croera, G. Gagliardi, P. Foti, R. Parchment, D. Parent-Massin, G. Schoeters, Y. Sibiril, R. Van Den Heuvel, and L. Gribaldo Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics Toxicol. Sci. 75 2003 355 367
33. M. Pirmohamed, S. Madden, and B.K. Park Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism Clin. Pharmacokinet. 31 1996 215 230
34. A.V. Pisciotta, S.A. Konings, L.L. Ciesemier, C.E. Cronkite, and J.A. Lieberman Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis J. Lab. Clin. Med. 119 1992 254 266
35. B. Sperner-Unterweger, S. Gaggl, W.W. Fleischhacker, C. Barnas, M. Herold, and D. Geissler Effects of clozapine on hematopoiesis and the cytokine system Biol. Psychiatry 34 1993 536 543
36. C.D. Thompson, M.T. Kinter, and T.L. Macdonald Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate Chem. Res. Toxicol. 9 1996 1225 1229
37. J.P. Uetrecht The role of leukocyte-generated metabolites in the pathogenesis of idiosyncratic drug reactions Drug Metab. Rev. 24 1992 299 366
38. J.P. Uetrecht New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system Chem. Res. Toxicol. 12 1999 387 395
39. J.P. Uetrecht Is it possible to more accurately predict which drug candidates will cause idiosyncratic drug reactions? Curr. Drug Metab. 1 2000 133 141
40. J.P. Uetrecht, H.M. Ma, E. MacKnight, and R. McClelland Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis Chem. Res. Toxicol. 8 1995 226 233
41. J.P. Uetrecht, N. Zahid, and D. Whitfield Metabolism of vesnarinone by activated neutrophils; implications for vesnarinone-induced agranulocytosis J. Pharmacol. Exp. Ther. 270 1994 865 872
42. M.D. Vincent, H.M. Clink, R.C. Coombes, I.E. Smith, R. Kandler, and T.J. Powles Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer Br. Med. J. 291 1985 105
43. D.P. Williams, M. Pirmohamed, D.J. Naisbitt, J.L. Maggs, and B.K. Park Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis J. Pharmacol. Exp. Ther. 283 1997 1375 1382
44. D.P. Williams, M. Pirmohamed, D.J. Naisbitt, J.P. Uetrecht, and B.K. Park Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine Mol. Pharmacol. 58 2000 207 216
45. P.A. Winstanley, J.W. Coleman, J.L. Maggs, A.M. Breckenridge, and B.K. Park The toxicity of amodiaquine and its principal metabolites towards mononuclear leukocytes and granulocyte/monocyte colony forming units Br. J. Clin. Pharmacol. 29 1990 479 485